Full Press Release Details
Announces Closing of Follow-On Offering
NEW YORK--(BUSINESS WIRE)--April 10, 2018--Regulatory News:
Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) (NASDAQ: CLLS - EURONEXT
GROWTH: ALCLS), a clinical-stage biopharmaceutical company focused on
developing immunotherapies based on gene-edited allogeneic CAR T-cells,
today announced the closing of its underwritten offering of 5,646,000
American Depositary Shares ("ADS") at a public offering price of $31.00
per ADS. The net proceeds to Cellectis from the offering are
approximately $163.7 million, after deducting the estimated expenses
related to the offering and the underwriting discounts and commissions
payable by Cellectis. In connection with the offering, Cellectis granted
the underwriters a 30-day option to purchase up to an additional 846,900
ADSs. The ADSs are listed on the Nasdaq Global Market under the symbol
"CLLS" and Cellectis' ordinary shares are listed on the Euronext Growth
market of Euronext in Paris under the symbol "ALCLS".
Goldman Sachs & Co. LLC, Citigroup and Barclays acted as book-running
managers for the offering. Nomura acted as lead manager and Oppenheimer
& Co. and Ladenburg Thalmann acted as co-managers.
A shelf registration statement on Form F-3 (including a prospectus)
relating to Cellectis' American Depositary Shares was filed with the
Securities and Exchange Commission (the "SEC") and has become effective.
A copy of the prospectus supplement (and accompanying prospectus)
relating to the offering may be obtained from Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, NY 10282,
or by telephone at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com,
Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, or by telephone at (800)
831-9146 or Barclays Capital Inc., c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at
(888) 603-5847 or by email at barclaysprospectus@broadridge.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. In particular, no public offering of the ADSs will be made
Special Note Regarding Forward-Looking Statements
This press release contains "forward-looking" statements that are based
on our management's current expectations and assumptions and on
information currently available to management. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements.
Further information on the risk factors that may affect company business
and financial performance is included in Cellectis' Annual Report on
Form 20-F for the year ended December 31, 2017, and subsequent filings
Cellectis makes with the SEC from time to time. Except as required by
law, we assume no obligation to update these forward-looking statements
publicly, or to update the reasons actual results could differ
materially from those anticipated in the forward-looking statements,
even if new information becomes available in the future.
For further information, please contact:
Jennifer Moore, 917-580-1088
Caitlin Kasunich, 212-896-1241
Simon Harnest, 646-385-9008
of Corporate Strategy and Finance